Vaccine therapy for small cell lung cancer Journal Article
| Author: | Krug, L. M. |
| Article Title: | Vaccine therapy for small cell lung cancer |
| Abstract: | One novel approach to the treatment of lethal residual disease in patients with small cell lung cancer (SCLC) relies on the induction of a host-immune response to attack chemoresistant tumor cells. Because of its neuroectodermal origin, SCLC has a number of specific antigens that could be capitalized on as immune targets. This article reviews two vaccine strategies currently in clinical study. The anti-idiotype vaccine to the GD3 gangiloside, BEC-2, has recently been tested in a phase III trial. In this trial, patients with SCLC who had completed initial chemotherapy were randomized to observation or vaccination with BEC-2 plus bacillus Calmette-Guerin adjuvant. A series of other trials have established the immunogenicity of several keyhole limpet hemocyanin conjugate vaccines relevant to SCLC, including GM2, Globo H, fucosyl GM1, and polysialic acid. To optimize an immune response against a broad range of tumor phenotypes, these components will be combined into a polyvalent vaccine. A randomized phase II trial of this polyvalent vaccine is planned to start in 2004. © 2004 Elsevier Inc. All rights reserved. |
| Keywords: | cancer survival; survival rate; clinical trial; review; cisplatin; nonhuman; antigen expression; phenotype; bcg vaccine; carboplatin; cancer immunotherapy; etoposide; lung neoplasms; clinical protocol; protein tyrosine kinase; tumor antigen; enzyme linked immunosorbent assay; monoclonal antibody; lung small cell cancer; immunological tolerance; immune response; immunoglobulin g; cancer vaccines; minimal residual disease; immunogenicity; cancer cell; antibody response; vaccination; polysialic acid; outcomes research; ganglioside gm1; corticosteroid; technique; ganglioside gd3; ganglioside gm2; antibody titer; keyhole limpet hemocyanin; hemocyanin; immunoglobulin m; vaccines, conjugate; carcinoma, small cell; glycolipid; adjuvant; gangliosides; glycoside; saponin; antibodies, anti-idiotypic; antiidiotypic antibody; humans; human; priority journal; bec 2; tumor extract |
| Journal Title: | Seminars in Oncology |
| Volume: | 31 |
| Issue: | 1 Suppl.1 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2004-02-01 |
| Start Page: | 112 |
| End Page: | 116 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 14981589 |
| DOI: | 10.1053/j.seminoncol.2003.12.022 |
| DOI/URL: | |
| Notes: | Semin. Oncol. -- Cited By (since 1996):18 -- Export Date: 16 June 2014 -- CODEN: SOLGA C2 - 14981589 -- Source: Scopus |
